Skip to main navigation
  • Events
  • Contact
  • Home
  • About us
  • Products
  • Partnering
  • Investors
    • Stock Information
    • Events & Presentations
    • Financial Information
      • Annual Reports
      • Results Center
      • SEC Filings
      • Listing Prospectus
    • Financial Calendar
    • Shareholder Meeting
    • Analyst Coverage
    • Corporate Governance
      • Committee Composition
    • Contact us
  • News
  • Events
  • Contact
  • Home
  • About us
    • Overview
    • Strategy
    • Management team
    • Board of Directors
    • Careers
  • Products
    • Overview
    • Autoimmunity
      • ARGX-113
    • Oncology
      • ARGX-110
      • ARGX-111
      • ARGX-115
    • Discovery programs
    • Technology
  • Partnering
    • Opportunities
    • Partnerships
    • Innovative Access Program
  • Investors
    • Stock Information
    • Events & Presentations
    • Financial Information
      • Annual Reports
      • Results Center
      • SEC Filings
      • Listing Prospectus
    • Financial Calendar
    • Shareholder Meeting
    • Analyst Coverage
    • Corporate Governance
      • Committee Composition
    • Contact us
  • News
    • Press releases
    • Events & Presentations
    • Downloads
  • Home
  • Investors
  •  
  • Listing Prospectus

Listing Prospectus

  
Date Documents
20/09/2018
  • Add Files
    Securities Note 448.4 KB
20/09/2018
  • Add Files
    Summary document 479.7 KB
20/09/2018
  • Add Files
    Registration Document 3.7 MB

Stock info

Read more 

FY 2018 Business Update & Financial Results

Replay webcast 

Innovative Access Program

Collaboration opportunities under our Innovative Access Program 
  • Print
  • RSS
  • Email Alerts
Contact

argenx SE
Breda, The Netherlands
T +31 763 030 488

info@argenx.com

 

argenx BVBA
Zwijnaarde, Belgium
T +32 9 310 34 00

Downloads
ARGX-113 poster MG Conference NY Annual report 2016 Corporate presentation
Follow us

2026 © argenx

| Disclaimer | Cookie policy | Sitemap
  • Home
  • About us
  • Products
  • Partnering
  • Investors
  • News
Created by Cantilis